GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PTC Therapeutics Inc.
Shares of PTC Therapeutics, a company that treats rare genetic diseases, are extremely volatile. Their price depends on the results of clinical trials and regulatory decisions regarding their drugs. The stock chart is a history of binary events, where news can either double or collapse the price.
Share prices of companies in the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases. We classify it in the Pharma Neurology sector. The chart below shows the overall performance of this biotech segment, not just PTC shares.
Broad Market Index - GURU.Markets
PTC Therapeutics is a biopharmaceutical company focused on developing treatments for rare genetic diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how PTC shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PTCT - Daily change in the company's share price PTC Therapeutics Inc.
Change_Co for PTC Therapeutics (PTCT), a biopharmaceutical company focused on rare diseases and neuroscience, reflects hypersensitivity to clinical results and regulatory approvals. PTCT's volatility is a measure of the extreme volatility inherent in innovative biopharma. This metric is critical for formulaic risk modeling.
Daily change in the price of a set of shares in a market segment - Pharma neurology
PTC Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with PTCT, which focuses on rare diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
PTC Therapeutics is a biopharmaceutical company specializing in drugs for rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing PTC Therapeutics' stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PTC Therapeutics Inc.
PTC Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Annual dynamics of market capitalization of the market segment - Pharma neurology
PTC Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs for rare diseases. Its success depends on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
PTC Therapeutics is a biotech company whose future depends on the success of its drugs for rare diseases. Its stock price is completely disconnected from economic cycles. The company's chart is a story of scientific breakthroughs, clinical trials, and regulatory decisions, not macroeconomic news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PTC Therapeutics Inc.
PTC Therapeutics, a biotech company specializing in the treatment of rare diseases, has sharp monthly fluctuations reflecting news about clinical trials, regulatory decisions, and the commercial success of its niche drugs.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
This chart reflects the dynamics of the biotech sector, particularly in the rare neurological diseases segment. For PTC Therapeutics, with its diversified portfolio, this is the backdrop. Its movements demonstrate how clinical trial successes and failures influence investor sentiment across the industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
PTC Therapeutics is a biopharmaceutical company specializing in drugs for rare diseases, particularly Duchenne muscular dystrophy. Its value is determined by the results of clinical trials. The overall market performance chart has little bearing on PTCT shares; their price is dependent on scientific news and regulatory decisions, which can cause sharp movements against the trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PTC Therapeutics Inc.
PTC Therapeutics is a biotech company specializing in rare diseases. Its weekly stock price is a tale of hope and disappointment. News about clinical trials and regulatory decisions cause extreme price fluctuations. The chart reflects the high risk and potential in the fight against rare diseases.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
PTC Therapeutics is part of the volatile biotech sector, where investor sentiment can shift across the entire industry. Key FDA decisions or scientific breakthroughs can lift or lower the entire segment. The chart shows how the company compares to the overall biotech industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
PTC Therapeutics is a biotech company focused on rare diseases. Its shares are surrounded by news about clinical trials and drug approvals. The chart clearly shows how the company's weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
PTCT - Market capitalization of the company PTC Therapeutics Inc.
The PTC Therapeutics stock chart is a roller coaster ride through the biotech world. Its market cap reflects the hopes and disappointments associated with developing drugs for rare genetic diseases. Every fluctuation on the chart represents the market's reaction to news about clinical trials and regulatory decisions.
PTCT - Share of the company's market capitalization PTC Therapeutics Inc. within the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. Its share of its segment's market capitalization reflects both current sales and investor confidence in its scientific developments. The chart below shows how successful clinical trials and regulatory approvals impact its market capitalization.
Market capitalization of the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases. How big is this niche? The chart below shows the overall market capitalization of the neuroscience sector. Its growth reflects massive investments in orphan diseases and hopes for breakthroughs in gene and RNA therapies.
Market capitalization of all companies included in a broad market index - GURU.Markets
The PTC Therapeutics chart illustrates the volatile history of rare disease drug development. The company's market capitalization is a roller coaster ride, where the success or failure of a single drug in clinical trials can double or halve the company's value. This chart illustrates the high risks and promises of orphan drug development.
Book value capitalization of the company, segment and market as a whole
PTCT - Book value capitalization of the company PTC Therapeutics Inc.
For PTC Therapeutics, a company focused on rare diseases, book value is its material foundation: research laboratories, manufacturing contracts, and, crucially, financial reserves for conducting expensive clinical trials. The chart below shows how the company built this foundation for its scientific research.
PTCT - Share of the company's book capitalization PTC Therapeutics Inc. within the market segment - Pharma neurology
PTC Therapeutics fights rare diseases, and its tangible assets include cutting-edge laboratories and manufacturing facilities for developing innovative drugs. These high-tech facilities are the physical foundation for saving lives. The chart shows the company's control over this specialized pharmaceutical infrastructure.
Market segment balance sheet capitalization - Pharma neurology
PTC Therapeutics is a biopharmaceutical company whose value lies in its development portfolio. It is a capital-light business. The chart below reflects the capital intensity of the entire pharmaceutical sector, highlighting its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
PTC Therapeutics develops drugs to treat rare genetic diseases. The company's balance sheet, comprised of research assets and capital, is small relative to the market. This stake in BCap_All represents a concentrated resource focused on creating hope for patients with orphan diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company. Its balance sheet is its R&D. Its market valuation is the value of its approved drugs for rare diseases and the hope for new ones. Its high price-to-market ratio is a premium on its ability to find solutions for previously hopeless patients.
Market to book capitalization ratio in a market segment - Pharma neurology
PTC Therapeutics is a biotech company specializing in treating rare diseases. Its value is based almost entirely on its scientific platform and the potential of its drug pipeline. The chart shows the huge premium to book value that investors are paying for the hope of a breakthrough.
Market to book capitalization ratio for the market as a whole
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. This chart reflects the average market valuation of the business. Against this backdrop, its valuation is highly volatile and depends on the results of clinical trials and regulatory decisions regarding its experimental drugs.
Debts of the company, segment and market as a whole
PTCT - Company debts PTC Therapeutics Inc.
For PTC Therapeutics, a biopharmaceutical company focused on rare diseases, debt management is vital. The company uses debt to fund expensive clinical trials and bring orphan drugs to market. This chart shows the financial effort behind developing drugs for patients with limited treatment options.
Market segment debts - Pharma neurology
PTC Therapeutics is a biotech company specializing in drugs for rare diseases. Developing such drugs is a lengthy and expensive process. The financial policy reflected in this chart shows the amount of capital the company raises to fund its clinical trials and bring life-saving drugs to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company specializing in rare diseases. Drug development in this field is a long and risky process. This chart shows the company's financial strategy: whether it relies on debt to fund its research, which can be risky until drugs are approved, or on equity.
Market segment debt to market segment book capitalization - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in drugs for rare diseases. This chart shows the overall debt burden in the niche orphan drug sector. It helps assess how companies finance their expensive research and how PTC's capital raising strategy compares to industry trends.
Debt to book value of all companies in the market
PTC Therapeutics, a biopharmaceutical company, requires significant capital for R&D in rare diseases. This chart shows the overall debt level, reflecting investors' willingness to finance risk. For PTC, this is an important context for how easy it is to raise funds for innovative but risky projects.
P/E of the company, segment and market as a whole
P/E - PTC Therapeutics Inc.
PTC Therapeutics, Inc. is a biopharmaceutical company specializing in the treatment of rare genetic diseases. This chart shows that the company's valuation is based on the commercial success of its drugs and the potential of its research pipeline. Investors are analyzing the potential for its unique treatments to become industry-standard.
P/E of the market segment - Pharma neurology
Developing drugs for rare diseases, like PTC Therapeutics's, is a high-risk business. This chart shows the average valuation for biopharmaceutical companies. It helps understand how the market values PTC's pipeline of approved drugs and its scientific pipeline compared to other companies operating in this complex niche.
P/E of the market as a whole
PTC Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases. Its valuation is entirely dependent on the success of its drugs and clinical trial data. Overall market sentiment, reflected in this chart, has virtually no bearing on the company's performance. PTC's fate is decided in labs and doctors' offices, not on the stock exchange.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. This chart reflects analyst expectations regarding the commercial success of its existing products and the clinical trial results of new candidates. It shows the future profit the market is pricing in based on scientific potential.
%20P%2FE%20PTC%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PTC-Therapeutics-Inc.&v=1772640078016 "Chart of the company's future (projected) P/E PTC Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for rare (orphan) diseases. This chart shows how its profitability expectations compare to the biotech sector. It reflects investor confidence in the commercial success of its existing products and the potential of its gene therapy research.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772640078022 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
PTC Therapeutics is a biopharmaceutical company specializing in drugs for rare diseases. This chart shows the company's overall risk appetite. PTC's success depends on clinical trial results and regulatory approvals. A positive market environment helps with funding but cannot guarantee a scientific breakthrough, which is the primary driver of valuation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772640078052 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company specializing in the development and commercialization of drugs for rare diseases. This chart shows the financial trajectory of the company, which operates in the orphan drug niche. The dynamics reflect the sales success of its approved drugs and the progress of clinical trials for new candidates.
Profit of companies in the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare genetic diseases, particularly in neuroscience. This chart shows the overall profitability of the pharmaceutical sector, reflecting the success of companies in creating breakthrough treatments for niche but highly targeted patient groups.
Overall market profit
PTC Therapeutics is a biopharmaceutical company specializing in rare diseases. Demand for its drugs is driven by patient medical needs, not the state of the economy. Orphan disease drugs are priced high and guaranteed to be covered by insurance. This makes PTC's business completely non-cyclical and insulated from the trends in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PTC Therapeutics Inc.
PTC Therapeutics is a biotechnology company specializing in developing drugs for rare genetic diseases. Its financial results depend on sales of already approved drugs and the success of clinical trials of new candidates. This chart shows analysts' expectations for the growth of its commercial pipeline.
%20profit%20of%20the%20company%20PTC%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PTC-Therapeutics-Inc.&v=1772640078273 "Graph of future (projected) profit of the company PTC Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare (orphan) diseases. This chart reflects forecasts for the biotech sector. Focusing on rare diseases allows PTC to operate in less competitive markets and receive special incentives, but requires significant investment in research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772640078309 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
PTC Therapeutics develops drugs to treat rare (orphan) diseases. Demand for its medications is driven solely by medical needs. However, this earnings curve, reflecting profit expectations, is significant. It impacts investor sentiment, the cost of capital, and the willingness of the healthcare system to cover the costs of expensive innovative treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772640078404 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company specializing in drugs for rare diseases. This chart shows how the company's valuation depends on the commercial success of its current products and the clinical trial results of its new candidates. It reflects investor expectations for future revenue growth.
P/S market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. The company's revenue depends on the success of its commercial products and clinical development. This chart reflects the average biotech valuation, helping to understand how the market views PTC Therapeutics' niche strategy and scientific potential compared to its peers.
P/S of the market as a whole
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for the treatment of rare (orphan) diseases. Its success depends on the approval and commercialization of niche drugs. This graph of average market revenue valuations contrasts sharply with PTC's market value, demonstrating investor confidence in the potential of its unique developments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company specializing in the development and commercialization of drugs for rare diseases. This chart shows how the market estimates future revenue, which depends on the success of its drugs in the market and progress in developing new therapeutics for patients with unmet medical needs.
%20P%2FS%20PTC%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PTC-Therapeutics-Inc.&v=1772640078641 "The graph of the company's future (projected) P/S PTC Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. This chart compares the company's future revenue expectations with its industry. It reflects the market's assessment of the commercial potential of its drug portfolio and the success of its research programs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772640078666 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
PTC Therapeutics is a biopharmaceutical company specializing in developing treatments for rare genetic diseases. This chart reflects confidence in future growth, and PTC exemplifies its source. The company's success in developing drugs for orphan diseases demonstrates how innovation opens new markets and brings hope to patients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772640078746 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs for rare diseases. The revenue shown in this chart is generated by sales of its approved drugs. This growth reflects the success of bringing these niche products to market.
Sales of companies in the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in developing treatments for rare genetic diseases. Their success depends on their ability to bring innovative drugs to market for patients with limited treatment options. This chart reflects the dynamics of the orphan disease niche, where a single drug can change the lives of thousands.
Overall market sales
PTC Therapeutics, a biopharmaceutical company specializing in rare diseases, relies on the healthcare system and investment. The resulting revenue growth improves the financial health of insurance companies and government programs, increasing their willingness to cover the high-cost, innovative drugs PTC develops and markets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of rare diseases, particularly genetic disorders. Its future sales forecast reflects market expectations for the commercial success of its existing and future drugs. This is a bet that its science will bring solutions to patients with previously incurable diseases.
%20sales%20of%20the%20company%20PTC%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PTC-Therapeutics-Inc.&v=1772640078824 "Schedule of future (projected) sales of the company PTC Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for the treatment of rare (orphan) diseases, particularly Duchenne muscular dystrophy. This chart shows forecasts for the pharmaceutical sector, allowing one to assess how PTC's focus on niche but critically important drugs is driving its growth potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772640078832 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
PTC Therapeutics, a biopharmaceutical company focused on rare diseases, sees this chart as a marker of the stability of the healthcare system. The positive economic forecasts reflected here ensure predictable funding for programs that cover the costs of expensive orphan disease treatments, which is critical for the company.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772640078894 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. Once its products are launched, its financial picture changes. This chart shows how successfully these niche drugs are commercialized, and how sales revenue begins to cover years of research investment and turn into profit.
Market segment marginality - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly Duchenne muscular dystrophy. This chart shows its financial performance in the context of the industry. The company's profitability is directly dependent on the success of its key drugs and the ability to expand their use into new markets.
Market marginality as a whole
PTC Therapeutics is a biotech company specializing in drugs for rare diseases. This graph shows average profitability, but PTC operates in a niche with a high unmet need. Their success depends on the approval and commercialization of drugs that can generate significant profits due to the lack of competition.
Employees in the company, segment and market as a whole
Number of employees in the company PTC Therapeutics Inc.
PTC Therapeutics is a biopharmaceutical company specializing in rare diseases. This chart shows the growth of its scientific and commercial teams. This increase reflects progress in clinical trials and the creation of an infrastructure for commercializing and marketing approved orphan disease drugs.
Share of the company's employees PTC Therapeutics Inc. within the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company focused on rare diseases, particularly in neuroscience. Its work requires unique scientific expertise. This chart shows the percentage of all specialists in the orphan disease niche that PTC has. This is a measure of its scientific potential and commitment to helping patients with rare diagnoses.
Number of employees in the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. Its core resource is its team of scientists and clinicians. This chart shows how the company is building its capabilities to advance drugs through complex research stages and bring them to market, reflecting the maturity of its pipeline.
Number of employees in the market as a whole
PTC Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases. Its success is determined by scientific breakthroughs and regulatory approvals. This chart shows the big picture, and PTC exemplifies a company where every employee, from scientists to clinicians, is dedicated to developing medicines for patients with limited treatment options.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PTC Therapeutics Inc. (PTCT)
PTC Therapeutics is a biopharmaceutical company specializing in rare diseases. Its high market capitalization, despite its small staff, reflects the market's valuation of its scientific developments and commercialized drugs. This chart shows the enormous cost per employee, typical of innovative biotech companies.
%20of%20the%20company%20PTC%20Therapeutics%20Inc.%20(PTCT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PTC-Therapeutics-Inc.-PTCT&v=1772640079246 "Chart of market capitalization per employee (in thousands of dollars) of the company PTC Therapeutics Inc. (PTCT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company focused on orphan diseases, particularly in neuroscience. This chart shows the average capitalization per employee in the sector. It demonstrates how much the market values their R&D and niche drug portfolio per scientist.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772640079353 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
PTC Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases. Its value is based on its pipeline of approved drugs and its scientific developments. This chart demonstrates a high market capitalization per employee, typical for biotech, where a successful drug for an orphan disease can generate significant revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772640079426 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PTC Therapeutics Inc. (PTCT)
PTC Therapeutics is a biopharmaceutical company specializing in orphan (rare) diseases, primarily in neurology. It's an R&D company. This chart shows how effectively a small team of scientists and managers can advance and commercialize drugs for niche markets where drug prices can be very high.
%20Chart%20PTC%20Therapeutics%20Inc.%20(PTCT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PTC-Therapeutics-Inc.-PTCT&v=1772640079589 "Company Profit Per Employee (in thousands of dollars) Chart PTC Therapeutics Inc. (PTCT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
PTC Therapeutics (PTCT) is a biotech company focused on rare (orphan) diseases (Duchenne muscular dystrophy). This chart shows the benchmark for "Pharma Neurology" (Biotech). In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high. This is the "blockbuster business," where a single patent on an orphan drug can generate billions.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772640079656 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
PTC Therapeutics (PTCT) is a biopharmaceutical company specializing in developing treatments for rare (orphan) genetic diseases, particularly Duchenne muscular dystrophy. This graph, showing average profit per employee, is important for biotech. It allows one to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772640079723 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PTC Therapeutics Inc. (PTCT)
PTC Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases. This chart tells the story of the transition from science to commercialization. Once a drug is brought to market, it shows how even a small team can generate significant revenue, given the high cost of treating orphan diseases.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PTC-Therapeutics-Inc.-PTCT&v=1772640079755 "Sales chart per company employee PTC Therapeutics Inc. (PTCT)")
Sales per employee in the market segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in rare (orphan) diseases, particularly in neurology. This chart shows the average revenue per employee in this segment. For a biotech company operating in the rare disease niche, this is an important indicator of how productive their commercial team is in reaching small but complex patient populations.
Sales per employee for the market as a whole
PTC Therapeutics, Inc. is a biotech company specializing in rare (orphan) diseases, specifically Duchenne muscular dystrophy. This chart shows how effectively their commercial team is selling these niche, but very expensive, drugs. It's an indicator of how R&D investments translate into real revenue.
Short shares by company, segment and market as a whole
Shares shorted by company PTC Therapeutics Inc. (PTCT)
PTC Therapeutics is a biopharmaceutical company specializing in orphan (rare) diseases, primarily in neurology. Its revenue depends on a few key drugs. The chart shows the number of investors who are skeptical of its portfolio. They may fear competition from gene therapy or failures in clinical trials of new drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PTC-Therapeutics-Inc.-PTCT&v=1772640079867 "Short Shares Chart for the Company PTC Therapeutics Inc. (PTCT)")
Shares shorted by market segment - Pharma neurology
PTC Therapeutics is a biotech company specializing in orphan diseases, often in neuroscience. This chart reflects the overall pessimism in biotech. It shows the general skepticism of investors: they may fear not only RTS failures but also regulatory or funding issues across the entire rare disease industry.
Shares shorted by the overall market
PTC Therapeutics is a biotech focused on rare diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs dependent on funding. This pessimism, visible on the chart, threatens the capital PTCT needs for research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PTC Therapeutics Inc. (PTCT)
PTC Therapeutics is a biotech company focused on rare diseases. The stock is volatile and dependent on R&D. This chart above 70 may reflect positive trial data. Oversold levels (<30) are often associated with research setbacks, regulatory delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PTC-Therapeutics-Inc.-PTCT&v=1772640079973 "RSI 14 indicator chart for the company's stock PTC Therapeutics Inc. (PTCT)")
RSI 14 Market Segment - Pharma neurology
PTC Therapeutics is a biopharmaceutical company specializing in developing treatments for rare (orphan) diseases, particularly neurological diseases like Duchenne muscular dystrophy. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole and how PTC stands out.
RSI 14 for the overall market
PTC Therapeutics is a biotech company specializing in rare (orphan) diseases. Its success depends on regulatory approval and drug commercialization. This chart shows the overall risk appetite in biotech. In times of panic, investors tend to sell off shares of companies whose revenue depends on future events rather than current sales.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PTCT (PTC Therapeutics Inc.)
PTC Therapeutics (PTCT) is a biopharmaceutical company focused on developing treatments for rare (orphan) diseases, particularly in neurology. This chart shows the average 12-month analyst forecast. The trend reflects their confidence in the success of clinical trials and the commercial potential of new drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PTCT-PTC-Therapeutics-Inc.&v=1772640080150 "A chart showing analyst consensus forecasts for the expected stock price. PTCT (PTC Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price PTCT (PTC Therapeutics Inc.)
PTC Therapeutics is a biotech company specializing in developing drugs to treat rare diseases, particularly RNA-based therapies. This chart shows analysts' forecasts for the stock's upside and downside. It measures the gap between the consensus price forecast and the current price, reflecting expectations for the success of their clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PTCT-PTC-Therapeutics-Inc.&v=1772640080193 "A chart showing the difference between the consensus forecast and the actual stock price. PTCT (PTC Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
PTC Therapeutics is a biotech company focused on developing drugs for rare neurological diseases, specifically Duchenne muscular dystrophy. This chart shows analysts' overall expectations across the pharmaceutical sector. It reflects whether experts believe in the success of R&D in the rare disease field.
Analysts' consensus forecast for the overall market share price
PTC Therapeutics is a biotech company specializing in drugs for rare (orphan) diseases. This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to fund unprofitable biotechs with high potential. Pessimism = risk aversion, and R&D capital dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PTC Therapeutics Inc.
PTC Therapeutics is a biotech company focused on developing and commercializing drugs for the treatment of rare (orphan) diseases, particularly in neuroscience and oncology. This chart is an assessment of their R&D pipeline. It reflects market expectations for their current sales and, more importantly, for the clinical trial results of their future drug candidates.
AKIMA Market Segment Index - Pharma neurology
PTC Therapeutics is a biotech focused on rare (orphan) diseases, particularly in neuroscience (e.g., Duchenne muscular dystrophy). This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does PTC's niche R&D strategy differentiate it from the average pharma company?
The AKIM Index for the overall market
PTC Therapeutics is a biotech company focused on rare genetic diseases, primarily in neurology (Duchenne muscular dystrophy). It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends.
